作者:Prem C. Srivastava、Michael V. Pickering、Lois B. Allen、David G. Streeter、Marie T. Campbell、Joseph T. Witkowski、Robert W. Sidwell、Roland K. Robins
DOI:10.1021/jm00212a014
日期:1977.2
glycosylthiocarboxamides were utilized as the precursors for the synthesis of 2-D-ribofuranosylthiazole-4-carboxamide and 2-beta-D-ribofuranosylthiazole-5-carboxamide (23). The structural modification of 2-beta-D-ribofuranosylthiazole-4-carboxamide (12) into 2-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)thiazole-4-carboxamide (15), 2-beta-D-ribofuranosylthiazole-4-thiocarboxamide (17), and 2-(5-deoxy-beta-D-ribofuranos
描述了在4-二甲基氨基吡啶存在下,糖基氰化物与液态硫化氢的一般反应,以提供相应的糖基硫代羧酰胺。这些糖基硫代羧酰胺被用作合成2-D-呋喃呋喃糖基噻唑-4-羧酰胺和2-β-D-呋喃呋喃糖基噻唑-5-羧酰胺的前体(23)。2-β-D-呋喃呋喃糖基噻唑-4-羧酰胺(12)的结构修饰为2-(2,3,5-三-O-乙酰基-β-D-呋喃呋喃糖基)噻唑-4-甲酰胺(15),2还描述了-β-D-呋喃呋喃糖基噻唑-4-硫代羧酰胺(17)和2-(5-脱氧-β-D-呋喃呋喃糖基)噻唑-4-甲酰胺(19)。测试了这些噻唑核苷对1型疱疹病毒,3型副流感病毒和13型鼻病毒的体外活性,并进行了针对副流感病毒的体内实验。他们还被评估为嘌呤核苷酸生物合成的潜在抑制剂。已显示具有最显着的抗病毒活性的化合物(12和15)也是鸟嘌呤核苷酸生物合成的活性抑制剂(40-70%)。